The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
 
Vera Hirsh
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
 
Eng-Huat Tan
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Ken O'Byrne
Stock and Other Ownership Interests - Blue Sky Biosciences; CARP Pharmaceuticals
Honoraria - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AZD; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AZD; Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Australian Provisional Patent Number 2015905380 entitled ‘Nucleic Acid Oligomers and Uses Thereof’; TCD Ref LO02-310-01; US patent 13/601,703 entitled ‘Global Analysis of Serum microRNAs as Potential Biomarkers for Lung Adenocarcinoma’
Travel, Accommodations, Expenses - AZD; Boehringer Ingelheim; MSD; Roche
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Novartis
Research Funding - Novartis; Pfizer
 
Michael J. Boyer
Research Funding - AstraZeneca; Boehringer Ingelheim; Genentech; Merck; Pfizer
Travel, Accommodations, Expenses - AstraZeneca
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Honoraria - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Consulting or Advisory Role - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
Ki Hyeong Lee
No Relationships to Disclose
 
Shun Lu
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche
 
Yuankai Shi
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose
 
Janessa J. Laskin
Research Funding - AstraZeneca (Inst); Lilly (Inst); Roche Canada (Inst)
 
Dong-Wan Kim
No Relationships to Disclose
 
Catherine Dubos Arvis
No Relationships to Disclose
 
Karl Kölbeck
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Martin H. Schuler
Honoraria - Alexion Pharmaceuticals; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Inanovate; Inanovate (Inst); Lilly; Lilly (Inst); Novartis; Novartis (Inst)
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - University Duisburg-Essen
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Inanovate; Lilly; Pfizer
 
Dan Massey
Employment - Boehringer Ingelheim
 
Angela Maerten
Employment - Boehringer Ingelheim
 
Luis Paz-Ares
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca